AGEN vs ELTX
AGEN: Agenus is a biotechnology company advancing a novel, multifunctional immunotherapy combination for difficult-to-treat cancers like MSS colorectal cancer. ELTX: Elicio Therapeutics is developing lymph node-targeted, off-the-shelf immunotherapies for mKRAS-driven solid tumors using its proprietary AMP technology platform.
Side-by-side fundamentals
| Metric | AGEN | ELTX | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $7.54 | $1.81 | |
| Market cap | $339M | $35M | |
| P/E as of 2026-10-08 | 4.52 | n/a | |
| Net margin | -2.7% | -1225.9% | AGEN higher |
| Operating margin | -17.7% | -1031.4% | AGEN higher |
| ROE FY2025, SEC XBRL | n/a | -2418.8% | |
| ROA FY2025, SEC XBRL | -1.4% | -153.0% | AGEN higher |
| Debt / equity as of 2026-09-03 | 4.01 | 5.75 | AGEN lower |
| Revenue growth (YoY) as of 2026-09-03 | +24.5% | -91.9% | AGEN higher |
| Revenue CAGR (3y) SEC XBRL | +5.2% | -10.6% | AGEN higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 1.55 | 0.51 | |
| 1-year return as of 2026-10-08 close | +80.8% | -82.8% | AGEN higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.